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Delivery represents a significant barrier to the clinical 
advancement of oligonucleotide therapeutics for the 
treatment of neurological disorders, such as Hunting-
ton’s disease. Small, endogenous vesicles known as 
exosomes have the potential to act as oligonucleotide 
delivery vehicles, but robust and scalable methods for 
loading RNA therapeutic cargo into exosomes are lack-
ing. Here, we show that hydrophobically modified small 
interfering RNAs (hsiRNAs) efficiently load into exo-
somes upon co-incubation, without altering vesicle size 
distribution or integrity. Exosomes loaded with hsiRNAs 
targeting Huntingtin mRNA were efficiently internalized 
by mouse primary cortical neurons and promoted dose-
dependent silencing of Huntingtin mRNA and protein. 
Unilateral infusion of hsiRNA-loaded exosomes, but not 
hsiRNAs alone, into mouse striatum resulted in bilateral 
oligonucleotide distribution and statistically significant 
bilateral silencing of up to 35% of Huntingtin mRNA. 
The broad distribution and efficacy of hsiRNA-loaded 
exosomes delivered to brain is expected to advance the 
development of therapies for the treatment of Hunting-
ton’s disease and other neurodegenerative disorders.
Received 6 June 2015; accepted 14 June 2016; advance online  
publication 9 August 2016. doi:10.1038/mt.2016.126
INTRODUCTION
A broad range of human diseases, including cancer or neurode-
generation, can be treated via the silencing of specific genes using 
small oligonucleotides. Oligonucleotide therapeutics (ONTs) are 
a new class of drugs, distinguished by targeting RNA or DNA, 
and thus preventing expression of the protein responsible for the 
disease phenotype. Expansion of CAG repeats in the huntingtin 
gene (HTT) causes Huntington’s disease (HD),1 a dominant neu-
rodegenerative disorder characterized by progressive abnormal 
movements, cognitive deficit, and depression.2,3 The mechanism 
of pathogenesis remains poorly understood,3 with the striatum 
and cortex being primary affected.2 Direct HTT mRNA targeting 
with ONTs and partial silencing of both wild-type and mutant 
HTT alleles in striatum and cortex is a promising strategy for HD 
treatment.4–7
One class of ONTs is small interfering RNA (siRNA), short 
RNA duplexes that are comprised of a passenger (sense) and a 
guide (antisense) strand. Upon cellular uptake, the guide strand is 
loaded into an RNA Induced Silencing Complex (RISC) capable 
of cleaving its complementary target mRNA. Loaded RISC is a 
multiple-turnover enzymatic complex. Recent studies estimate 
that as few as 25–100 active RISCs can provide efficient long-
term silencing in vitro and in vivo.8,9 Despite significant promise, 
the clinical utility of siRNA for the treatment of neurodegenera-
tive disorders is hampered by inefficient CNS tissue delivery and 
distribution.10,11
Hydrophobically modified siRNAs (hsiRNAs) are asymmetric 
oligonucleotides with chemical modifications that improve stabil-
ity and promote cellular internalization.12 A cholesterol moiety, 
conjugated to the 3′ end of the passenger strand, enables rapid 
membrane association, and the single-stranded phosphorothio-
ate tail promotes cellular internalization by a mechanism simi-
lar to that used by conventional antisense oligonucleotides.13 We 
have recently demonstrated that these compounds efficiently 
bind  cellular membranes, enter cells, and induce potent gene 
 silencing.14 A bolus intrastriatal injection of Htt-targeting hsiRNA 
induces local Htt mRNA silencing; however, this activity is limited 
to ipsilateral side of the brain, as significant hydrophobicity drives 
hsiRNA retention around the site of injection.14
Exosomes have recently emerged as a promising vehicle for 
siRNA delivery. These endogenously produced, extracellular ves-
icles mediate intercellular communication by transferring lipids, 
proteins, and RNAs between cells.15,16 Exosomes have been isolated 
from diverse body fluids, including cerebrospinal fluid (CSF), and 
play a crucial role in physiological and pathological processes.15,16 
Exploiting the natural properties of exosomes, particularly the 
ability to functionally transport small RNAs,17–19 might offer an 
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alternative solution for improving oligonucleotide brain distri-
bution and neuronal uptake.20–27 Electroporation or loading of 
synthetic siRNAs and microRNAs into naturally secreted extra-
cellular vesicles has been shown to promote cellular uptake and 
target gene silencing.28–30 Yet a lack of robust, scalable methods to 
load exosomes with artificial siRNAs has impeded development of 
exosomes as a viable delivery vehicle.
Here, we decided to explore if the membrane binding ability 
of hsiRNA could be exploited to enable exosomal loading with the 
synthetic siRNAs. We demonstrate that simple co-incubation of 
hsiRNAs with exosomes is an efficient method for productive and 
controlled loading of exosomes with chemically synthesized oli-
gonucleotide cargo. Exosomes loaded with hsiRNAHTT targeting 
Htt mRNA mediate nontoxic internalization of hsiRNAHTT and 
dose-dependent silencing of Htt mRNA and protein in primary 
cortical neurons, a cell type that is traditionally difficult to trans-
fect.31 Unilateral infusion of hsiRNAHTT-loaded exosomes into the 
striatum results in bilateral distribution of hsiRNAHTT in both stri-
atal and cortical regions, associated with statistically significant 
bilateral silencing of Htt mRNA in the striatum. Thus, our data 
provide a path toward the use of exosomes for delivery of ONTs to 
treat neurodegenerative disorders.
RESULTS
hsiRNAs efficiently load into exosomes
hsiRNAs are asymmetric siRNAs, with a short duplex region 
(12–15 base pairs) and a single-stranded, fully phosphorothio-
ated tail, where all pyrimidines are modified with 2′-fluoro 
or 2′-O-methyl (providing stabilization and avoidance of 
a protein kinase R response32). The 3′ end of the passenger 
strand is conjugated to a bioactive hydrophobic conjugate 
(TEG–Cholesterol).12 The cholesterol enables quick membrane 
association, while the single-stranded phosphorothioated tail is 
essential for cellular internalization by a mechanism similar to 
that used by conventional antisense oligonucleotides (Ly et al., 
2016; In review) (Figure 1a and Table 1). The sequences and 
chemical modification patterns of compounds used in this study 
are shown in Table 1. The ability of hsiRNAs to interact with 
cellular membranes prompted us to test whether hsiRNAs could 
efficiently load into exosomes. We purified exosomes by differ-
ential centrifugation of conditioned media from glioblastoma 
U87 cells (Supplementary Figure S1a).33 Nanoparticle track-
ing analysis and electron microscopy showed that the purified 
exosomes are homogeneous in size, with an average diameter of 
~140 nm (Figure 1, Supplementary Figure S1b and Table 2), 
and exhibit a characteristic cup shape33 (Supplementary 
Figure S1c). Size exclusion chromatography of exosomes and of 
conditioned media before and after ultracentrifugation showed 
that differential centrifugation precipitates most vesicles of this 
size (Supplementary Figure S1d).
Freshly purified U87-derived exosomes were incubated 
with 10 µmol/l Cy3-hsiRNAHTT (Figure 1a,b). hsiRNAHTT was 
recently identified in a screen and targets position 10150 of 
the human HTT mRNA sequence.14 Ultracentrifugation of 
the Cy3-hsiRNAHTT-exosome mixture generated a bright red 
pellet, confirming the association of fluorescently labeled 
hsiRNA with the high-molecular-weight vesicles (Figure 1b,c, 
Supplementary Figure S2b). A Cy3-hsiRNAHTT pellet was 
observed only in the presence of exosomes (Supplementary 
Figure S2b), indicating the absence of detectable non-
loaded hsiRNA aggregation. Consistent with its role in pro-
moting membrane interactions, the cholesterol moiety was 
required for loading of Cy3-hsiRNAHTT into exosomes and 
non- cholesterol conjugates hsiRNAs did not associate with 
Figure 1  Efficient loading of exosomes with hsiRNAs. (a) hsiRNAHTT schematic and PyMOL model. (b) Flowchart of exosome loading procedure: 
co-incubation of Cy3-hsiRNA and exosomes results in Cy3-hsiRNA-loaded exosomes that pellet by ultracentrifugation. (c) Bar graphs showing the 
percent of Cy3-hsiRNA or Cy3-hsiRNA-exosomes in the pellet (black) and supernatant (white) after ultracentrifugation (n = 3; mean ± SD). (d) hsiRNA 
loading does not affect exosome size distribution (nonloaded exosomes, solid line; hsiRNA-loaded exosomes, dashed line). (e) Electron microscopy 
of exosomes in the absence (left) or presence (right) of hsiRNA. Exosomes remain intact when loaded with hsiRNA (scale bar = 100 nm). hsiRNA, 
hydrophobically modified small interfering RNA.
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exosomes (Supplementary Figure S2c). The majority of hsiR-
NAHTT-loaded exosomes suspended in phosphate-buffered 
saline (PBS) were stable, with about 80% of Cy3 fluorescence 
signal remaining associated with the vesicles after repetitive 
ultracentrifugation (Supplementary Figure  S2a). About 10–
50% of the hsiRNA in solution associated with exosomes; this 
estimation was based on the concentration of hsiRNA remain-
ing in solution after loading (relative pellet and solution fluo-
rescence). We estimate that ~1,000 to 3,000 hsiRNAs associate 
with each exosome with 3,000 being close to saturation (Figure 
1c and Table 2).
Exosomes loaded with hsiRNAs were similar in size (Figure 1d) 
and shape (Figure 1e) to unloaded exosomes. Electron micros-
copy of exosomes loaded with biotinylated hsiRNAs and labeled 
with streptavidin-gold revealed that hsiRNAs are present both 
on the surface and in the lumen of hsiRNA-loaded exosomes 
(Supplementary Figure S3). We observed a significantly higher 
percent with gold particles on the outside and the inside of exo-
somes incubated with biotin-hsiRNAs compared to exosomes 
unloaded with hsiRNA. These data suggest that while the major-
ity of hsiRNAs bind the exosome membrane, some are present 
in the lumen of exosomes as well. Consistent with the presence 
of hsiRNAs on the surface of exosomes, the surface charge (zeta 
potential) of the hsiRNA-loaded exosomes was lower than that 
of unloaded exosomes (Table 2). Taken together, these data 
indicate that the cholesterol moiety promotes efficient and sta-
ble loading of chemically synthesized siRNAs onto exosomes 
by simple co-incubation without disrupting the overall vesicle 
integrity.
hsiRNA-loaded exosomes efficiently enter into 
primary neurons and induce silencing of both Htt 
mRNA and HTT protein
To determine if hsiRNA-loaded exosomes efficiently enter pri-
mary cortical neurons, we prepared fluorescently labeled hsiR-
NAHTT-loaded exosomes, in which hsiRNAHTT was labeled with 
Cy3 (red), and exosomes were labeled with the lipophilic dye 
PKH67 (green). hsiRNAHTT-loaded exosomes were added to the 
culture medium (Figure 2a, Supplementary Figure S4), and 
the levels of intracellular fluorescence intensity were monitored 
by confocal microscopy. We prepared a PKH67 sample (without 
exosomes) and samples of PKH67-labeled exosomes in the same 
way. The PKH67 control did not produce any detectable cellular 
labeling compared to PKH67-labeled exosomes (Supplementary 
Figure S4, top and middle panel). The kinetics of internalization 
of exosomes, loaded or not with hsiRNAHTT, were comparable, 
indicating that the incorporation of oligonucleotide cargo did 
not significantly interfere with the exosomal uptake properties 
(Supplementary Figure S4, middle panel). To evaluate the impact 
of exosomal loading on the kinetics and efficiency of hsiRNA 
uptake, primary neurons were treated with nonloaded and exo-
some-loaded Cy3-hsiRNAs. We found that hsiRNAHTT-loaded 
exosomes enter primary neurons (Figure 2a,b). Although there 
might be a short delay early in the kinetic, by 6 hours, there is 
no more difference detected between hsiRNAHTT and hsiRNAHTT-
exosome (Figure 2a,b, Supplementary Figure S4, lower panel).
We measured colocalization of PKH67 (exosomes marker) 
and Cy3 (hsiRNA marker) and observed that >62% of fluores-
cence colocalized 24 hours after cells were treated with hsiR-
NAHTT-loaded exosomes. This indicates that significant fraction of 
hsiRNAHTT-loaded exosomes remains stable inside the cells.
To evaluate the impact of hsiRNAHTT-loaded exosomes con-
centration on efficiency of hsiRNAHTT neuronal uptake, the 
neuronal Cy3-hsiRNA was measured at 4 days post-treatment 
(high- performance liquid chromatography (HPLC), see Materials 
and Methods) (Figure 2c). The efficiency of cellular internalization 
was nonlinear, and the capacity of neurons to take up hsiRNAHTT-
loaded exosomes appeared saturable (Figure 2c). This finding is 
consistent with the kinetics of uptake observed with microscopy 
(Figure 2a,b).
Table 1 Table describing hsiRNA target, sequences and modifications, and PNA strand
Target
Compounds
Strand Sequence 5′–3′ ConjugateName Type
Nontargeting control hsiRNANTC hsiRNA S mA.mC.A.A.A.mU.A.mC.G.A.mU#mU#Ma Cholesterol
AS PmU.A.A.fU.fC.G.fU.A.fU.fU.fU.G.mU#mC#A#A#mU#mC#A
Huntingtin siRNAHTT siRNA S mC.mA.G.mU.A.A.A.mG.A.G.A.mU.mU#mA#Ma None
AS PmU.fU.A.A.fU.fC.fU.fC.fU.fU.fU.A.fC.fU#G#A#fU#A#fU#A
Huntingtin hsiRNAHTT hsiRNA S mC.mA.G.mU.A.A.A.mG.A.G.A.mU.mU#mA#Ma Cholesterol
AS PmU.fU.A.A.fU.fC.fU.fC.fU.fU.fU.A.fC.fU#G#A#fU#A#fU#A
sFlt-1 hsiRNAsFlt1 hsiRNA S Not published Cholesterol
AS Not published
Antisense hsiRNAHTT PNAHTT PNA S Cy3-OO-*T*A*T*A*T*C*A*G*T*A*A*A*T*A*G*A*T*T*A*A None
m, 2′-O-methyl; f, 2′-fluoro; #, phosphorothioate; P, phosphate; *, peptidyl interaction; hsiRNA, hydrophobically modified small interfering RNA; PNA, peptide 
nucleic acid; S, sense; AS, antisense.
Table 2 Table describing the characteristics of nonloaded and  
hsiRNA-loaded exosomes, including surface charge (Zetasizer, Malvern)
Unloaded 
exosomes
hsiRNA-loaded 
exosomes
Particles number (µl) 109 109
hsiRNAs (molecules/vesicle) — 1,000–3,000
Mean size (nm) 141 145
Zeta potential (mV) −13 −32
hsiRNA, hydrophobically modified small interfering RNA.
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Figure 2 Internalization of hydrophobic Cy3-hsiRNA-loaded exosomes by primary cortical neurons. (a) Kinetics of Cy3-hsiRNAHTT-loaded exo-
somes shows significant co-localization between exosomes and hsiRNAs. hsiRNAHTT labeled with Cy3 (red); exosomes labeled with PKH67 (green); 
nuclei labeled with Hoechst (blue). Samples were visualized at 63× magnification. Scale bar = 10 µm. Arrows show hisRNAHTT-exosomes. (b) Bar graphs 
showing the absolute quantification of Cy3-fluorescence in cells upon incubation with Cy3-hsiRNA (black) or Cy3-hsiRNA-exosomes (white) (n = 5; 
mean ± SD; *P < 0.05, **P < 0.01, paired t-test comparing the Cy3 intensity of hsiRNA nonloaded versus loaded in exosomes). (c) Quantification of 
Cy3-hsiRNAHTT taken up by primary neurons with increasing amounts of Cy3-hsiRNAHTT-loaded exosomes. The level of Cy3-labeled hsiRNAs was mea-
sured by high-performance liquid chromatography (n = 3 technical replicates; mean ± SD). hsiRNA, hydrophobically modified small interfering RNA.
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Figure 3 Concentration-dependent silencing of Huntingtin mRNA and protein by hsiRNAHTT-loaded exosomes in primary cortical neurons. 
(a) Graph of Htt mRNA levels in cells treated with increasing amounts of hsiRNAHTT-loaded exosomes (solid line), hsiRNANTC-loaded exosomes (dot-
ted line), or nonloaded exosomes (dashed line) for 7 days. Htt mRNA levels are normalized to Ppib mRNA (housekeeping control) and presented as 
percent of untreated control (n = 4 biological replicates, each performed with n = 3 technical replicates; mean ± SD; *P < 0.05, **P < 0.01, paired 
t-test comparing each concentration to hsiRNANTC-loaded exosomes). (b) Graph of HTT protein levels in cells treated with increasing amounts of 
hsiRNAHTT-loaded exosomes (solid line; n = 5 biological replicates) or hsiRNANTC-loaded exosomes (dotted line; n = 3 biological replicates) for 7 days. 
HTT signal was normalized to Tubulin. Data at each concentration are presented as percent of untreated control samples (mean ± SD; *P < 0.05, 
**P < 0.01, paired t-test comparing each concentration to untreated samples). hsiRNA, hydrophobically modified small interfering RNA; NTC, non-
targeting control.
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To assess whether exosome-mediated hsiRNAHTT delivery 
productively silences Htt mRNA and protein, we treated mouse 
primary cortical neurons for 7 days with increasing doses of hsiR-
NAHTT-loaded exosomes (Figure 3). As a negative control, cells 
were treated with exosomes loaded with nontargeting hsiRNANTC. 
We observed dose-dependent silencing of Htt mRNA (up to 75% 
reduction; Figure 3a) and HTT protein (up to 68% reduction; 
Figure 3b and Supplementary Figure S5 for original Western 
blot). Neither hsiRNAHTT alone nor hsiRNAHTT-loaded exosomes 
affected the expression levels of housekeeping controls (Ppib 
mRNA and Tubulin protein; Supplementary Figure S5). We esti-
mated that exosome-associated hsiRNAHTT induced Htt mRNA 
silencing with a half-maximal inhibitory concentration (IC50) in 
the low nanomolar range, which required treatment with at least 
25 × 108 exosomes per well (Figure 3a). These results suggest that 
exosomes support efficient neuronal delivery and do not interfere 
with hsiRNA-RISC assembly or hsiRNA-mediated silencing.
hsiRNA-loaded exosomes distribute bilaterally in the 
brain upon unilateral brain infusion
Saturable uptake of exosomes by neurons might be advanta-
geous for in vivo delivery and promote wide distribution of oli-
gonucleotides throughout the brain. To test this, we infused 
Cy3-hsiRNAHTT-loaded exosomes directly into mouse striatum 
for 7 days (0.5 µg hsiRNA/day) and then examined the distri-
bution of hsiRNAs throughout the brain. Unilateral delivery of 
Cy3-hsiRNAHTT-loaded exosomes led to bilateral distribution of 
fluorescence throughout the brain, including the striatum and 
cortex (Figure 4a). We did not observe fluorescence in brains 
infused with unlabeled hsiRNAHTT-loaded exosomes (Figure 4b), 
demonstrating that fluorescence is due to the Cy3-hsiRNAHTT 
rather than an increase in tissue autofluorescence.
Structural damage at the infusion site was similar in all treated 
brains, including those treated with PBS. A high level of fluo-
rescence appeared to accumulate around the infusion site. This 
Figure 4 Exosomes promote bilateral distribution of hsiRNAs. (a,b) Images of ipsilateral (left) and contralateral (right) brain sections after infusion of 
Cy3-hsiRNAHTT-loaded exosomes (red) (a) or unlabeled hsiRNAHTT-loaded exosomes (b). Nuclei stained with Hoechst (blue). Samples were visualized at 
2.5× magnification. Scale bar = 1 mm. All pictures were acquired with the same microscope settings. (c,d) Plot showing tissue concentrations of hsiR-
NAHTT (c) or hsiRNAsFlt1 (d) guide strands measured by peptide nucleic acid hybridization in biopsies from the ipsilateral (IL) and contralateral (CL) striata of 
mice treated with hsiRNA-loaded exosomes, hsiRNAs alone, or artificial cerebrospinal fluid (CSF) (hsiRNAHTT, n = 7 mice per group; hsiRNAsFlt1, n = 9 mice 
per group). Each point in the plot represents the level of hsiRNA guide strands in an individual mouse, and the mean ± SD of each group is indicated. 
Data were analyzed using a nonparametric Kruskal–Wallis test, and the mean of each column was compared to the mean of the corresponding artificial 
CSF control column. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. hsiRNA, hydrophobically modified small interfering RNA.
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local accumulation might result in part from direct exposure 
to exosomes or exosomal degradation and local release of Cy3-
hsiRNAs. A single unilateral injection of Cy3-hsiRNA alone (i.e., 
not loaded into exosomes) also resulted in a local accumulation 
of fluorescence proximal to the injection site but fluorescence 
was not detected contralateral to the injection site.14 Thus, exo-
somes deliver hsiRNAs to both sides of the brain after unilateral 
administration.
To quantitatively confirm the observed exosome-dependent 
bilateral hsiRNA distribution, we used a PNA-based hybridiza-
tion assay. This assay directly quantifies the levels of hsiRNA 
guide strand tissue acummulation34 (Figure 4c,d). A week after 
infusion, we harvested striata from mice infused with hsiRNAHTT-
loaded exosomes, hsiRNAHTT alone (nonloaded), or artificial CSF 
(aCSF) (control). Nonloaded hsiRNAs accumulated in the ipsilat-
eral striata, but not in the contralateral striata. The guide strand of 
hsiRNAHTT delivered by exosomes was detected in both ipsilateral 
and contralateral striata, consistent with bilateral fluorescence of 
Cy3-labeled guide strand detected in situ (Figure 4c). We obtained 
similar results using a different hsiRNA, hsiRNAsFlt1, targeting the 
sFlt-1 mRNA (Figure 4d). Together these data suggest that local 
infusion of hsiRNA-loaded exosomes supports widespread deliv-
ery of hsiRNAs throughout the brain.
hsiRNAHTT-loaded exosomes induce bilateral Htt 
mRNA silencing in vivo
To determine whether the bilateral distribution of hsiR-
NAHTT results in widespread Htt mRNA silencing, we infused 
hsiRNAHTT-loaded exosomes (0.5 or 1 µg/day) into the striata 
of wild-type mice for 7 days (Figure 5). As controls, we infused 
aCSF, unloaded exosomes, hsiRNANTC-loaded exosomes (nontar-
geting control), or nonformulated hsiRNAHTT (0.5 and 1 µg/day). 
At the end of the treatment, we measured Htt mRNA levels in ipsi-
lateral and contralateral striata and compared to aCSF-treated or 
hsiRNANTC-loaded exosomes samples (Figure 5, Supplementary 
Table S1). Treatment with hsiRNAHTT-loaded exosomes resulted 
in statistically significant bilateral reduction of Htt mRNA at 
both concentrations used (Figure 5, Supplementary Table S1). 
Bilateral silencing triggered by hsiRNAHTT-loaded exosomes is 
consistent with the bilateral distribution of fluorescent hsiRNA-
loaded exosomes described above (Figure 4). At the doses tested, 
hsiRNAHTT did not reduce Htt mRNA levels—not even ipsilat-
eral to the injection site—indicating that exosomes are essen-
tial for hsiRNAs distribution and function throughout the brain 
(Figure 5). Silencing induced by hsiRNAHTT-loaded exosomes 
was similarly significant when compared to aCSF-treated animals 
(Supplementary Table S1). These findings demonstrate that the 
exosome-mediated bilateral hsiRNA distribution was functionally 
significant.
hsiRNA-loaded exosomes do not induce measurable 
cytotoxicity or innate immune activation
A viable delivery vehicle should have minimal innate immuno-
stimulation and cytotoxicity. We measured the levels of microg-
lia activation and cell death after administering exosomes to the 
brain (Supplementary Figures S6–S8). Microglia and monocytes 
Figure 5 hsiRNAHTT-loaded exosomes induce bilateral Htt mRNA silencing in vivo in mouse brain. (a) Plots showing Htt mRNA levels in biopsies from 
the ipsilateral (closed) and contralateral (open) striata of mice treated with artificial cerebrospinal fluid (CSF), unloaded exosomes, hsiRNANTC-loaded 
exosomes, 0.5 and 1 µg/day hsiRNAHTT, or 0.5 and 1 µg/day hsiRNAHTT-loaded exosomes (red). Exosomes were delivered at 2–4 × 1010 particles/day. 
Level of Htt mRNA was normalized to Ppib mRNA (housekeeping control), and data are presented as percent of untreated control (n = 6–10 mice per 
group). Each point represents the averaged level of Htt mRNA from three biopsies of an individual mouse, and the mean ± SD of each group is indicated. 
(b) Bonferroni’s multiple comparison tests between groups treated with artificial CSF, exosomes, hsiRNAHTT, or hsiRNAHTT-exosomes and group treated 
with hsiRNANTC-loaded exosomes. IL, ipsilateral; CL, contralateral; hsiRNA, hydrophobically modified small interfering RNA; NTC, nontargeting control.
ba
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are activated by brain injury and can be identified by Iba1 stain-
ing, a marker of neuroinflammation.35 Activated microglia show 
increased Iba1 staining, enlarged cell bodies, and ramified pro-
cesses. Because some of the innate immune response may be 
transient and disappear by 7 days postinjection, we evaluated 
the microglia response at 6 hours after injection of hsiRNAHTT-
loaded exosomes (Supplementary Figure S6). The histopathol-
ogy and morphology of microglia staining were comparable 
between mice injected with PBS, exosomes alone, or hsiRNAHTT-
loaded exosomes (Supplementary Figure S6). Visual evaluation 
of treated and untreated brains did not show any inflammatory 
events (Supplementary Figure S6a,b). Intracranial injection with 
PBS caused a marginal activation of microglia in the ipsilateral 
side of the brain, mostly related to needle-induced trauma. The 
number of activated microglia was increased by exosomes alone 
but not by hsiRNAHTT-loaded exosomes, suggesting a minor neu-
roinflammation enhanced by exosomes only (Supplementary 
Figure S6c). This effect was minor and fully resolved by 7 days 
(Supplementary Figure S7).
To assess the impact of exosome-mediated delivery of oligo-
nucleotides on neuronal integrity, we stained for the dopamine 
receptor DARPP32, a marker for neuronal viability expressed on 
medium spiny neurons in the striatum (Supplementary Figure S8). 
The histopathology and quantification of DARPP32-positive cells 
was comparable between mice infused with PBS, exosomes alone, 
or hsiRNAHTT-loaded exosomes (Supplementary Figure S8); we 
did not observe any negative impact on DARPP32 staining in all 
samples.
DISCUSSION
The discovery that extracellular vesicles mediate the transport of 
functional small RNAs between cells has raised considerable inter-
est for exosomes to serve as a novel delivery vehicle for therapeu-
tic oligonucleotides.36 Methods of loading oligonucleotides into 
exosomes have included electroporation29,37 or overexpression of 
siRNA in exosome-producing cells.38–40 Though useful for proof-
of-principle experiments, neither method can be easily controlled 
or scaled for production.41 Moreover, electroporation was shown 
to disrupt exosome integrity,41 thereby dampening enthusiasm for 
the potential utility of exosomes for therapeutic oligonucleotide 
delivery.
We have shown that co-incubating hsiRNAs with exosomes 
provides a robust, efficient, and highly reproducible method for 
loading exosomes with chemically synthesized oligonucleotides. 
We believe that this methodology could easily be used to load 
other classes of therapeutic oligonucleotides, including micro-
RNAs, antisense oligonucleotides, antagomirs, or aptamers, as 
long as the oligonucleotides are stable and hydrophobically modi-
fied. The simplicity of this method should accelerate research into 
the use of exosomes for delivery of ONTs.
The hsiRNA-loaded exosomes are stable during the prepara-
tion and the loading of the vesicles with the oligonucleotides did 
not interfere with their physical (size, appearance) or functional 
(trafficking, brain distribution) properties (Figures 1 and  2). 
Efficient loading requires extensive chemical stabilization of siR-
NAs. Indeed hsiRNAs have >60% of ribose’s chemically modi-
fied with 2′-O-methyl and 2′-fluoro modifications resulting in 
significant resistance to nuclease degradation.12 With increase in 
the hsiRNA/vesicle loading ratio, we have seen a slight increase 
in surface negative charge indicating that hsiRNAs associate with 
vesicle membrane. This is consistent with electron microscopy 
that confirmed presence of oligonucleotides on the surface and 
in the lumen of exosomes; hsiRNA-loaded exosomes are stable 
and externally bound hsiRNAs are resistant to nucleases. At 
this point, we cannot define which of the exosomes-associated 
oligonucleotides (surface bound or internalized) are function-
ally active. The amount of hsiRNA associated with exosomes is 
affected by hsiRNA/exosomes ratio during the loading procedure. 
The loading is saturatable and a maximum of ~3,000 hsiRNA can 
be loaded per individual vesicle. Too much loading might inter-
fere with native exosome-uptake mechanism as the loading of 
hsiRNAs does influence the surface charge of exosomes. Further 
studies are essential to determine the optimal loading, long-term 
stability, and in vivo behavior of the hsiRNA-loaded exosomes.
What is the mechanism of exosomes driven bilateral brain dis-
tribution? Retrograde transport of hsiRNAHTT-loaded exosomes 
along nerve fiber tracts could account for the presence of hsiR-
NAHTT in cortical layers on both sides of the brain, and antero-
grade transport could promote the spread of hsiRNAHTT to the 
contralateral striatum.42 Although significantly more fluorescence 
accumulated ipsilateral to the infusion site than contralateral, the 
level of intact guide strand, detected using PNA hybridization 
assay34 (Figure 4c,d), and Htt mRNA silencing (Figure 5) were 
generally similar on both sides of the brain. The excess of fluores-
cence around the injection site likely reflects local accumulation of 
the Cy3-hsiRNAHTT degradation products, as levels of full-length 
guide strands were similar. Further enhancement of hsiRNA sta-
bility should allow development of loading in vesicles with better 
distribution and efficacy.
The contralateral distribution of hsiRNAs is dependent on 
their loading in exosomes. Infusion of equal amounts of non-
loaded hsiRNAs did not result in detectable transfer of oligonucle-
otides to the noninjected side of the brain. Most of the nonloaded 
hsiRNAs stayed at the injected side of the brain and relatively high 
levels are easily detectable by the PNA hybridization assay (Figure 
4). Intact oligonucleotides were detectable, but were functionally 
inactive at the same dose (Figure 5). This might be related to 
preferentially binding of cholesterol-modified oligonucleotides to 
hydrophobic myelinated fibers, limiting neuronal access. In bolus 
injection, a large amount of oligonucleotides is delivered simulta-
neously saturating the tissue matrix, with excess of the oligonucle-
otides available for functional neuronal trafficking. Similar trends 
were observed with antisense oligonucleotides, where bolus injec-
tion supported better efficacy and functional tissue accumulation 
than slow, continuous infusion with the pumps.14 In the ipsilateral 
side of the brains, hsiRNAs loaded in exosomes accumulated to 
the similar or even lower levels than nonloaded oligonucleotides. 
The level of accumulation was lower, but sufficient to support Htt 
mRNA silencing. This indicates that hsiRNAs loaded in exosomes 
traffic differently from unloaded hsiRNAs in vivo.
Our hope is that exosome-mediated delivery of oligonucle-
otides can reduce the effective concentration of oligonucleotide 
required for silencing in the brain. In a recent study, infusion of 
700 µg of antisense oligonucleotide was required to efficiently 
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silence Htt mRNA.5 We have shown here that infusion of as little 
as 3.5–7 µg of hsiRNAHTT over 1 week (1 µg/day) is sufficient to 
reduce Htt mRNA levels by ~35%, but only when hsiRNAs are 
loaded in exosomes. Our findings therefore suggest that exosomes 
increase hsiRNA stability, promote in vivo bilateral spreading of 
hsiRNAs, and enter a potent neuronal uptake pathway. The bilat-
eral efficacy was consistent with exosome-mediated distribution 
of mature guide strands to both sides of the brain as detected by 
PNA hybridization assay (Figure 4b).
We only observed partial modulation of Htt mRNA expres-
sion (~35%) on both sides of the brain. While moderate, the 
silencing was highly statistically significant when compared to 
aCSF and exosomes formulated with nontargeting control (NTC). 
Further optimization of hsiRNA stability, loading, and explora-
tion of different exosome sources will likely increase the efficiency 
of silencing. Partial Htt mRNA silencing (40–50%) in vivo was 
previously demonstrated to be sufficient to prevent or delay dis-
ease phenotypes, neuropathology, and behavior abnormalities in 
several mouse models of HD.4–6 Clinically, it is likely that only 
partial HTT mRNA silencing will be optimal as complete gene 
elimination could be detrimental long-term.43,44
Translation of exosome-based therapeutics to the clinic will 
require identification of cell types, culture conditions, and puri-
fication methods that allow large-scale production of exosomes 
with minimal immunogenicity. Here, we used exosomes derived 
from the human U87 glioblastoma cell line. U87 cells produce a 
high level of exosomes and U87-derived exosomes are efficiently 
loaded with hsiRNA and show trafficking abilities into neurons.
We used human-derived exosomes in mouse and did not 
observe any significant increase in neuroinflammation levels over 
levels induced by infusion (aCSF versus hsiRNA-loaded exosomes, 
Supplementary Figures S6 and S7). There was minor, revers-
ible increase in numbers of activated microglia (Supplementary 
Figure S6) at the injection side of animals treated with exosomes 
(not loaded with hsiRNAs). hsiRNA-loaded exosomes did not 
show the same effect. Interestingly, heavily modified oligonucle-
otides have been shown to dampen immune response.45
We recognize that use of tumor-derived exosomes might raise 
concerns for clinical applications. There are multiple publications 
indicating roles of tumor-derived exosomes in cancer pathogene-
sis.46 We are currently screening different clinically acceptable cell 
sources, including mesenchymal stem cells, to produce exosomes. 
Thus, a next challenge is optimizing the production of exosomes 
of high quality and purity from other cell sources (examples 
include stem cells and dendritic cells). A better understanding of 
exosome components responsible for neuronal uptake could lead 
to engineered vesicles with similar properties. Neural stem cells 
or exosomes derived from stem cells are being considered as a 
therapeutic modality for the treatment of stroke47,48 or neurode-
generative disorders.37,49 The data presented here allow additional 
loading of exosomes with chemically synthesized therapeutic siR-
NAs or microRNAs.
In conclusion, here we describe a novel method for efficient 
loading of oligonucleotide cargo onto exosomes and the ability of 
exosomes to deliver cargo in vitro in primary neurons and in vivo 
in mouse brain. The ability of this “natural” oligonucleotide deliv-
ery strategy to promote the distribution and improve the efficacy 
of oligonucleotides represents an important step toward devel-
opment of novel therapies for HD and other neurodegenerative 
disorders.
MATERIALS AND METHODS
Oligonucleotides. Oligonucleotide sequences and chemical modification 
patterns used in this study are described in Table 1.
Cell culture. U87 glioblastoma cells were maintained in Dulbecco’s modi-
fied essential medium (DMEM) (Cellgro, Corning, NY; #10-013CV) sup-
plemented with 100 U/ml penicillin-streptomycin (Invitrogen, Carlsbad, 
CA; #15140) and 10% fetal bovine serum (Gibco, Carlsbad, CA; #26140) 
at 37 °C, 5% CO2, and 100% humidity. For the production of exosomes, 
glioblastoma cells were cultured in exosome-free medium prepared with 
DMEM supplemented with 400 U/ml penicillin-streptomycin and 40% 
fetal bovine serum, and ultracentrifuged in 70 ml polycarbonate bottles 
(Beckman Coulter, Brea, CA; #355622) overnight at 100,000g, 4 °C using 
a Type 45 Ti rotor (Beckman Coulter; #339160). The supernatant, corre-
sponding to 4× culture medium, was filtered in 0.2 µm filter bottle and 
diluted with DMEM to obtain 1× medium.50
Preparation of primary cortical neurons. Primary cortical neurons were 
isolated from E15.5 mouse embryos of wild-type FVBNj mice. Pregnant 
females were anesthetized by intraperitoneal injection of Avertin at 250 mg/
kg body weight (Sigma, St. Louis, MO; #T48402) followed by cervical dis-
location. Embryos were removed and transferred to ice-cold DMEM/F12 
medium (Invitrogen; #11320). Brains were removed and meninges were 
carefully detached. Cortices were isolated and transferred into prewarmed 
papain solution for 25 minutes at 37 °C, 5% CO2 to dissolve the tissue. Papain 
(Worthington, Lakewood, NJ; #54N15251) was dissolved in 2 ml Hibernate 
E (Brainbits, Springfield, IL; #HE) and 1 ml EBSS (Worthington; #LK003188) 
and supplemented with 0.25 ml of 10 mg/ml DNase1 (Worthington; 
#54M15168) in Hibernate E. After the 25-minute incubation, the papain 
solution was removed and 1 ml NbActiv4 (Brainbits; #Nb4-500) supple-
mented with 2.5% fetal bovine serum was added to the tissue. Tissues were 
then dissociated by trituration through a fire-polished, glass Pasteur pipet. 
Neurons were counted and diluted at 1 × 106 cells/ml. For live-cell imaging 
studies, 2 × 105 cells were plated in glass-bottom dishes (MatTek, Ashland, 
MA; #P35G-1.5-10-C) precoated with poly-l-lysine (Sigma; #P4707). For in 
vitro silencing assays, 1 × 105 neurons per well were plated on 96-well plates 
precoated with poly-l-lysine (BD BIOCOAT, Corning, NY; #356515). After 
overnight incubation at 37 C, 5% CO2, an equal volume of NbActiv4 sup-
plemented with anti-mitotics, 0.484 µl/ml of 5′UtP (Sigma, St Louis, MO; 
#U6625) and 0.2402 µl/ml of 5′FdU (Sigma, St Louis, MO; #F3503) was 
added to neuronal cultures to prevent the growth of non-neuronal cells. Half 
of the volume of media was replaced with fresh NbActiv4 containing anti-
mitotics every 48 hours until the experiments were performed.
Purification and characterization of exosomes. Exosomes were puri-
fied from U87 glioblastoma cells as described33,51 (Supplementary Figure 
S1A). Conditioned culture medium containing exosomes was harvested 
and centrifuged at 300g for 10 minutes. The supernatant was then centri-
fuged at 10,000g, 4 °C for 30 minutes and filtered in a 0.2 µm filter bottle. 
The filtered medium was centrifuged in 70 ml polycarbonate bottles for 
at least 70 minutes at 100,000g, 4 °C using a Type 45 Ti rotor (Beckman 
Coulter). Pellets were suspended in 1 ml PBS and centrifuged for 1 hour 
at 100,000g, 4 °C in a tabletop ultracentrifuge using a TLA-110 rotor 
(Beckman Coulter; #366730). Pellets were suspended in PBS for further 
experiments. For each sample, the concentration and size of particles 
were determined by recording and analyzing the Brownian motion of 
particles using a NanoSight NS300 system and Nanoparticles Tracking 
Analysis software (Malvern, Worcestershire, United Kingdom) accord-
ing to the manufacturer’s protocol. Samples were diluted in 1 ml PBS at 
room temperature and monitored in duplicate for 30 seconds with manual 
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shutter and gain adjustments. The recorded videos were analyzed using 
a Nanoparticle Tracking Analysis software. Particle charges were deter-
mined by diluting sample in 1 ml water and measuring the zeta potential 
in the universal glass cuvette Dip Cell kit (Malvern; #ZEN1002) using a 
Zetasizer Nano NS (Malvern).
Loading of exosomes with hsiRNAs and fluorescent labeling. Exosomes 
were loaded with indicated concentration of Cy3-fluorescent hsiRNAs 
in PBS by incubation at 37 °C for 90 minutes with shaking at 500 rpm. 
Unloaded hsiRNAs were separated from hsiRNA-loaded exosomes by 
ultracentrifugation for 1 hour at 100,000g, 4 °C in a tabletop ultracentri-
fuge using a TLA-110 rotor (Figure 1). Unloaded hsiRNAs remain in the 
supernatant and hsiRNA-loaded exosomes form a pellet (Supplementary 
Figure S2b). Pellets were suspended in PBS for in vitro uptake experiments 
or in cell medium for in vitro silencing analysis. The Cy3 fluorescence of 
the supernatant (containing unloaded hsiRNA) and the pellet (containing 
hsiRNA-exosomes) was measured in a Costar UV-transparent, flat-bottom 
96-well plate (Corning; #3635) using an Infinite M1000 Pro spectropho-
tometer (Tecan, Männedorf, Switzerland; 547 nm excitation and 570 nm 
emission wavelengths), using a calibration curve for the quantification. 
The loading efficiency of hsiRNAs in exosomes was estimated by two 
methods. First, by directly measuring the Cy3 fluorescence in the hsiRNA-
exosomes pellet. Second, by calculating the difference between the total 
amount of Cy3-hsiRNA originally added to the sample and the amount of 
Cy3-hsiRNA remaining in the supernatant after exosome incubation and 
ultracentrifugation.
The exosomes concentration was measured by Nanoparticle Tracking 
Analysis using a Nanosight (Malvern). The number of hsiRNAs loaded 
per exosomes was estimated by dividing the total amount of hsiRNAs in 
the sample by the number of exosomes detected by Nanoparticle Tracking 
Analysis, assuming normal distribution. The experimental input was always 
normalized by the amount of hsiRNA added (loaded or not), with level of 
hsiRNA loading being similar between different exosomes preparations.
Animal stereotaxic injections. All animal procedures were approved by 
the University of Massachusetts Medical School Institutional Animal Care 
and Use Committee (protocol number A-2411). Prior to oligonucleotide 
injection, animals were deeply anesthetized with 1.2% Avertin (Sigma; 
#T48402). For direct injection, wild-type FVBNj mice received microinjec-
tions by stereotactic placement into the right striata (coordinates relative 
to bregma were 1.0 mm anterior, 2.0 mm lateral, and 3.0 mm ventral). For 
brain infusion, ALZET osmotic pumps (ALZET, Cupertino, CA; #1007D) 
were prefilled with 100 µl of sample following manufacturer instructions 
and primed overnight at 37 °C in a water bath. Oligonucleotide was deliv-
ered at a flow rate of 0.5 µl/hour for 7 days.
For in vivo silencing of Htt mRNA, mice were treated with aCSF (100 
µl per pump, n = 9 mice), 20–30 × 109 particles/day of exosomes alone 
(100 µl per pump, n = 9 mice), 1 µg/day of NTC siRNA associated with 
20–30 × 109 particles/day of exosomes (100 µl per pump, n = 10 mice), 0.5 
or 1 µg/day hsiRNAHTT alone (100 µl per pump, n = 10 mice and n = 8 
mice per group, respectively), and 0.5 or 1 µg/day of hsiRNAHTT associated 
with 20–30 × 109 particles/day of exosomes (100 µl per pump, n = 9 mice 
and n = 6 mice per group, respectively). Upon 7 days of treatment, mice 
were killed and brains were harvested and processed as described below.
For analysis of immunoreactive DARPP32 and Iba1 neurons, mice 
received injections or pump infusion (100 µl) of either PBS or aCSF (2 μl 
per striata, or 100 µl per pump, n = 5 mice), 20–30 × 109 particles/day of 
exosomes alone (2 μl per striata, or 100 µl per pump, n = 5 mice), or of 
hsiRNAHTT-exosomes (2 μl per striata or 100 µl per pump, n = 5 mice). 
Mice were killed 6 hours or 7 days later.
mRNA quantification. The mRNA levels were quantified using the 
QuantiGene 2.0 Assay (Affymetrix, Santa Clara, CA; #QS0011).
For in vitro experiments, cells were plated at 1 × 105 neurons per 
well in 96-well plate and lysed in 250 μl diluted lysis mixture per well 
(Affymetrix; #13228) supplemented with 0.167 μg/μl proteinase K 
(Affymetrix; #QS0103) for 30 minutes at 55 °C. Cell lysates were mixed 
thoroughly and 40 μl (~16,000 cells) of lysate was added to the capture 
plate along with 40 μl additional diluted lysis mixture without proteinase 
K. Probe sets were diluted as specified in the Affymetrix protocol. Twenty 
microliters of mouse Htt or Ppib probe sets (Affymetrix; #SB-14150, #SB-
10002) was added for a final volume of 100 μl per sample well.
For in vivo experiments, brains were harvested and sliced from 
the front into 300 μm coronal sections using a Leica Vibratome 2000T 
(Leica Biosystems, Wetzlar, Germany). The fourth section from the front 
corresponds to the beginning of the striatum. The next three consecutive 
coronal sections (fifth, sixth, and seventh sections) were selected to collect 
one 2 mm biopsy from the striatum of each hemisphere of each section 
(i.e., three biopsies per animal per hemisphere) using a sterile disposable 
biopsy punch with plunger (Miltex, York, PA; #33-31-P) and placed in 
RNAlater (Ambion, Carlsbad, CA; #AM7020) for 24 hours at 4 °C. The 
position of the biopsy is strictly fixed and samples were always collected 
from the same region of the brain for all animals. All samples were stored in 
RNAlater at −80 °C until further analysis. Tissue biopsies were lysed in 300 
μl homogenizing buffer (Affymetrix; #10642), supplemented with 2 μg/μl 
proteinase K per 5 mg tissue punch, and homogenized in 96-well plate 
format on a TissueLyser II (Qiagen, Hilden, Germany). Forty microliters 
each lysate was added to the capture plate and mixed with 60 μl of diluted 
Htt or Ppib probe sets for a final volume of 100 μl. Signal was amplified 
according to the Affymetrix QuantiGene protocol. Luminescence was 
detected on a Veritas Luminometer (Promega, Madison, WI). The average 
of the three biological replicates (three biospsies) represents the mRNA 
expression value per animal.
Protein level quantification. Primary cortical neurons were plated 
at 1 × 105 neurons per well in 96-well plates and treated as described in 
Figure 3. Upon 7 days treatment, cells were lysed in 20 μl lysis buffer 
(50 mmol/l Tris pH 7.4, 250 mmol/l NaCl, 1% NP40, 5 mmol/l ETDA) 
supplemented with protease inhibitors (1 tablet per 10 ml buffer; Roche, 
Basel, Switzerland; #11836170001). Plates were incubated 15 minutes on 
ice, with shaking. Cell lysates from technical triplicates were pooled and 
stored at −80 °C until Western blots were performed. Lysates (20 µg) were 
boiled, then proteins were separated on Novex NuPage 3–8% Tris-Acetate 
gels (Life Technologies, Carlsbad, CA; #EA03755) and transferred to 
nitrocellulose using a TransBlot Turbo apparatus (BioRad, Hercules, CA; 
#1704155). Nitrocellulose membranes were blocked in 5% blotting grade 
blocker (BioRad; #1706404) in Tris-buffered saline, 0.1% Tween-20 (TBST) 
for 1 hour at room temperature and then incubated overnight in primary 
antibody diluted in blocking solution. The blots were cut horizontally, and 
the top of each blot was incubated with rabbit polyclonal anti-HTT anti-
body Ab1 (ref. 52) (1:2,000 in blocking buffer), while the bottom of each 
blot was incubated with mouse monoclonal anti-tubulin antibody (1:6,000 
in blocking buffer; Sigma) as a loading control. Blots were washed in TBST 
and then incubated with either peroxidase-labeled anti-rabbit IgG diluted 
(1:2,500 in blocking buffer) or anti-mouse IgG diluted (1:5,000 in block-
ing buffer) for 1 hour at room temperature. Blots were washed in TBST, 
and bands illuminated using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Carlsbad, CA; #34080) were captured on 
X-ray film. Images were scanned using an Epson Perfection V750 Pro 
(Epson, Tokyo, Japan), and densitometry was performed on manually 
identified bands using ImageJ software (NIH, Bethesda, MA).
PNA hybridization assay. hsiRNA guide strands in tissue lysates were 
quantified using a PNA hybridization assay (developed by Axolabs GmbH, 
Kulmbach, Germany).34 PNAs are analogues of DNA in which the sugar-
phosphate backbone is replaced with a polyamide backbone. Tissues 
were lysed in MasterPure Tissue Lysis Solution (EpiCentre, Madison, 
WI; #MTC096H) supplemented with 2 mg/ml proteinase K (Invitrogen; 
#25530-049) on a TissueLyser II (10 mg tissue in 100 µl lysis solution). 
Sodium dodecyl sulfate was precipitated with 3 mol/l KCl and pelleted at 
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5,000g. hsiRNA guide strands in cleared supernatant were hybridized to 
fully complementary Cy3-labeled PNA strands (PNABio, Thousand Oaks, 
CA). The PNA sequence and chemical modification pattern used in this 
study are described in Table 1. hsiRNA-PNA duplexes were injected into 
HPLC DNAPac PA100 anion exchange column (Thermo Scientific), and 
Cy3 fluorescence was monitored and peaks integrated. The mobile phase 
for HPLC was 50% water, 50% acetonitrile, 25 mmol/l Tris-HCl (pH 8.5), 
1 mmol/l ethylenediaminetetraacetate, and the salt gradient was 0–800 
mmol/l NaClO4. For the calibration curve, a known amount of hsiRNA 
duplex was spiked into tissue lysis solution.
Live cell staining. To monitor live-cell uptake of exosomes in vitro, exo-
somes or Cy3-labeled hsiRNA-loaded exosomes were fluorescently labeled 
with PKH67 dye (Sigma; #PKH67GL-1KT) by adding 10 µmol/l of PKH67 
to the samples in 100 µl PBS, and incubated for 30 minutes at 37 °C. 
Free dye was washed from labeled exosomes using MV3000 Exosome 
Spin Column (Life Technologies; #4484449) according to the manufac-
turer’s protocol. Primary neurons were plated at a density of 2 × 105 cells 
per 35-mm glass-bottom dish (MatTek; #P35G-1.5-10-C) precoated with 
poly-l-lysine (Sigma; #P4707). Nuclei were stained using the NucBlue 
Live ReadyProbe (Life Technologies; #R37605) according to the manu-
facturer’s recommendation. Imaging was performed in 1 ml phenol red-
free Hibernate E (Brainbits; #HE-Pr). Cells were treated with 0.2 µmol/l 
Cy3-labeled hsiRNA loaded in exosomes, 0.2 µmol/l Cy3-labeled hsiRNA 
alone, or exosomes, and live cell imaging was performed over time.
Immunohistochemistry of brain sections.  In vivo cytotoxicity and microg-
lia activation were monitored staining for immunoreactive DARPP32 and 
Iba1 proteins. Mice were perfused with PBS followed by paraformalde-
hyde, and brains were collected and randomized for single-blind process-
ing and analysis. Brains were sliced into 40-µm sections in ice-cold PBS 
through the striatum using a Leica Vibratome 2000T (Leica Biosystems) 
(ref. Allen Brain Atlas). Immunohistochemistry was performed on every 
sixth section at room temperature unless stated.
For Iba1, sections were blocked with 5% normal goat serum and 
1% bovine serum albumin in 0.2% Triton-X-100 and 0.03% hydrogen 
peroxide in PBS for 1 hour, washed with PBS, and incubated with anti-Iba1 
(1:1,000 in blocking solution; Wako, Osaka, Japan; #019-19741) overnight 
at 4 ºC. Sections were washed with PBS and incubated in biotinylated goat 
anti-rabbit secondary antibody (Vector Laboratories, Burlingame, CA) in 
PBS (1:200 dilution) for 10 minutes. After washing with PBS, biotinylated 
secondary antibody was labeled with peroxidase using the Vectastain 
ABC Kit (Vector Laboratories). Sections were washed with PBS, and 
peroxidase was visualized with 3,3ʹ-diaminobenzidine (DAB) using the 
Metal Enhanced DAB Substrate Kit (Pierce, Rockford, IL).
For DARPP32 immunohistochemistry, sections were washed for 
3 minutes in 3% hydrogen peroxide, and 20 minutes in 0.2% TritonX-100, 
and then blocked for 4 hours in PBS containing 1.5% normal goat serum. 
Sections were incubated with DARPP32 antibody (Abcam, Cambridge, 
United Kingdom; #40801) in 1.5% normal goat serum (1:10,000 dilution) 
at 4 ºC overnight. Washes, binding of secondary anti-rabbit antibody, and 
labeling and detection of peroxidase were performed as described above.
Stained sections were mounted and visualized using a Nikon Eclipse 
E600 microscope under a 20× objective and imaged using a Nikon Digital 
Sight DSRi1 camera (Nikon, Tokyo, Japan). Four images were taken 
of ipsilateral and contralateral striata in each section. The number of 
DARPP32-positive neurons and Iba1-positive microglia was quantified 
using ImageJ (NIH). Full-brain coronal section scans were acquired with 
a Coolscan V-ED LS50 35mm Film Scanner (Nikon).
Confocal imaging. For the analysis of hsiRNA uptake in vitro, images 
were acquired with a Leica DM IRE2 confocal microscope using a 63× oil-
immersion objective. Images were processed using ImageJ (1.47v) software 
(NIH). The relative uptake of hsiRNA, loaded or not in exosomes, was esti-
mated based on pixel-integrated density of five images for each condition. 
The percentage of colocalization was calculated based on Manders Overlap 
Coefficient using the Manders Coefficients plugin in ImageJ.
Size exclusion chromatography. Exosomes from U87 supernatants were 
purified as described above. Fifty microliters of cell-conditioned medium 
or 50 µl of exosomes was injected onto BioSep SEC-s4000 column (size 
exclusion column, pore size 500 Å) (Phenomenex, Torrance, CA) on an 
Agilent 1100 HPLC system (Agilent, Santa Clara, CA). Chromatography 
was conducted with 0.75 ml/minute flow rate with PBS as mobile phase. 
Eluted fractions were monitored at 220 nm using an Agilent DAD G1315B 
absorbance detector (Agilent).
Anion exchange chromatography. Primary cortical neurons were plated 
at 1 × 105 cells/well in a 96-well plate and treated with Cy3-labeled hsiRNA 
alone or with Cy3-labeled hsiRNA-loaded exosomes. After 4 days of incu-
bation, media were transferred to a new 96-well plate, and the cells were 
lysed in Cell and Tissue Lysis Solution (EpiCentre; #MTC096H) contain-
ing proteinase K (Invitrogen; #25530-049). Sodium dodecyl sulfate from 
the lysis buffer was precipitated by 3 mol/l KCl and pelleted at 5,000g. 
Supernatant was injected onto a Dionex DNAPac P100 anion exchange 
column. Chromatography was performed using an Agilent 1100 HPLC 
system at 1 ml/minute flow rate in 50% water, 50% acetonitrile, 25 mmol/l 
Tris-HCl, pH 8.8, 1 mmol/l ethylenediaminetetraacetate, and salt gradient 
from 80 to 800 mmol/l NaclO4. Cy3 fluorescence was detected in eluted 
fractions using an Agilent FLD1260 G1321B detector (Agilent).
Electron microscopy. Samples and grids for electron microscopy were pre-
pared at room temperature unless otherwise specified. An equal volume 
of 4% paraformaldehyde was added to the exosome sample and incubated 
for 2 hours. Aliquots of exosomes (3 µl) were dropped onto grids and incu-
bated in 2% paraformaldehyde for 20 minutes. The grids were transferred 
to a wax strip and washed with 100 µl PBS. The grids were incubated in 
50 mmol/l glycine/PBS for 5 minutes and blocked in 5% bovine serum 
albumin/PBS for 10 minutes in presence or absence of 0.1% saponin. The 
grids were washed twice in PBS and incubated with 6-nm or 10-nm strep-
tavidin immune-gold particles diluted 1:10 to 1:20 in 0.5% bovine serum 
albumin/PBS for 1 hour in presence or absence of 0.1% saponin. The grids 
were washed three times in PBS and incubated in 1% glutaraldehyde for 
5 minutes. Following eight washes with water of 2 minutes each, the grids 
were incubated in uranyl oxalate for 5 minutes, and then in a 9:1 solu-
tion of 1% methyl cellulose and 4% uranyl acetate for 10 minutes on ice. 
Excess liquid was removed with a filter paper and the grids were air-dried 
for 5–10 minutes. Exosomes were examined in a JEOL 1100 transmis-
sion electron microscope (JEOL, Peabody, MA) at 60 kV, and images were 
obtained with an AMT digital camera (Advanced Microscopy Techniques, 
Woburn, MA). The number of exosomes with gold particles on the out-
side and inside of the exosome, as well as the total number of exosomes 
per field (6.83 µm2), were counted for each condition (n = 1,593 exosomes 
in 16 fields for biotinylated hsiRNA; n = 1,234 exosomes in 15 fields for 
unloaded exosomes). The percent of exosomes with streptavidin gold par-
ticles per field was determined.
Statistical analysis. Data were analyzed using GraphPad Prism 6, version 
6.04 (GraphPad Software Inc., La Jolla, CA).
In in vitro silencing experiments, the IC50 values were determined 
by fitting dose–response curve using “log(inhibitor) versus response—
variable slope (four parameters)” equation. The bottom of the curve was 
set to be no less than zero and the top of the curve was set to be no >100.
The hsiRNA in vivo distribution data, monitored using PNA assay, 
were analyzed using a nonparametric Kruskal–Wallis test. The mean 
of each column was compared to the mean of the corresponding aCSF 
control column. For each mouse experiment, the level of silencing at 
each hsiRNA dose was normalized to the mean of the control group—the 
noninjected side in those mice treated with aCSF. In vivo silencing data 
were analyzed using the one-way analysis of variance test (Bonferroni’s 
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test for multiple comparisons). The mean of each column was compared 
to the mean of the corresponding hsiRNANTC-exosome control column. 
In vivo innate immune response data were analyzed with an unpaired 
t-test. Differences in all comparisons were considered significant at 
P values <0.05.
SUPPLEMENTARY MATERIAL
Figure S1. Exosome purification and characterization.
Figure S2. Cholesterol is necessary for efficient loading and interac-
tion of hsiRNAs into exosomes.
Figure S3. Electron microscopy validates presence of hsiRNAs at the 
surface and in the lumen of exosomes.
Figure S4. Efficient internalization of PKH67-labeled exosomes and 
Cy3-hsiRNAs in primary cortical neurons.
Figure S5. Concentration dependent silencing of huntingtin protein 
by hsiRNAHTT-loaded exosomes in primary cortical neurons.
Figure S6. Injection of exosomes and hsiRNAHTT-loaded exosomes 
have a slight impact on innate immune response in vivo.
Figure S7. Pump implantation for the infusion of exosomes and 
hsiRNA-loaded exosomes have no statistically significant impact on 
innate immune response in vivo.
Figure S8. Exosomes and hsiRNAHTT-loaded exosomes have no 
impact on cell viability in vivo.
Table S1. hsiRNAHTT-loaded exosomes induce bilateral Htt mRNA 
silencing in vivo in mouse brain.
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